Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific SessionsGlobeNewsWire • 11/17/19
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 ResultsGlobeNewsWire • 11/12/19
Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/19
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic AcidGlobeNewsWire • 09/05/19
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 DiabetesGlobeNewsWire • 08/29/19
Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of SharesGuruFocus • 08/02/19
Credit Suisse Best Ideas List Still Has 50% Implied Upside for These Stocks24/7 Wall Street • 07/03/19
Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/07/19
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 05/08/19
Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug ApplicationsBenzinga • 05/06/19
Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/30/19